Novel Artificial Pancreas Cuts HbA1c, Hypoglycemia in T1DM

Share this content:
Novel Artificial Pancreas Cuts HbA1c, Hypoglycemia in T1DM
Novel Artificial Pancreas Cuts HbA1c, Hypoglycemia in T1DM

FRIDAY, Nov. 3, 2017 (HealthDay News) -- A novel adaptive artificial pancreas (AP) can reduce hemoglobin A1c (HbA1c) in adults with type 1 diabetes (T1D), according to a study published online Oct. 13 in Diabetes Care.

Eyal Dassau, Ph.D., from Harvard University in Cambridge, Mass., and colleagues developed and tested a novel adaptive AP in an uncontrolled, multicenter 12-week clinical trial. A total of 30 adults with T1D completed a continuous glucose monitor (CGM)-augmented one-week sensor augmented pump (SAP) period. Basal insulin delivery settings used by the AP for initialization were adapted weekly after the AP was started, and every four weeks the carbohydrate ratios were adapted by an algorithm. Expert study clinicians and patients reviewed the adaptations.

The trial was completed by 29 patients. The researchers found that HbA1c was 7.0 ± 0.8 percent at the start of AP use, and after 12 weeks, improved significantly to 6.7 ± 0.6 percent. CGM time spent in the hypoglycemic range improved during the day and overnight from 5.0 to 1.9 percent and from 4.1 to 1.1 percent, respectively, compared with the SAP run in. Basal insulin was adapted throughout, while carbohydrate ratios were adapted to a larger extent initially, with minimal changes thereafter. About 10 percent of the adaptation recommendations were overridden manually. No protocol-related serious adverse events occurred.

"Use of our novel adaptive AP yielded significant reductions in HbA1c and hypoglycemia," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries, and two authors disclosed patents and patent applications. Several companies provided equipment for the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Dozens of Medical Groups Join Forces to Improve Diagnoses

Dozens of Medical Groups Join Forces to Improve ...

Diagnostic error is the most common cause of medical errors that patients report

HbA1c Variability Is a Strong Predictor of Mortality in T2DM

HbA1c Variability Is a Strong Predictor of Mortality ...

HbA1c variability is a powerful, independent measure, regardless of how it is measured

Pediatric End-Stage Liver Disease Score Underestimates Mortality

Pediatric End-Stage Liver Disease Score Underestimates Mortality

Actual probability of death for patients on liver transplant wait list underestimated by up to 17%

is free, fast, and customized just for you!




Already a member?

Sign In Now »